Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01781572
Recruitment Status : Completed
First Posted : February 1, 2013
Results First Posted : August 12, 2020
Last Update Posted : December 7, 2020
Sponsor:
Information provided by (Responsible Party):
Pfizer

Tracking Information
First Submitted Date  ICMJE January 24, 2013
First Posted Date  ICMJE February 1, 2013
Results First Submitted Date  ICMJE May 6, 2020
Results First Posted Date  ICMJE August 12, 2020
Last Update Posted Date December 7, 2020
Study Start Date  ICMJE June 2013
Actual Primary Completion Date January 15, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 24, 2020)
  • Number of Dose Limiting Toxicities (Phase Ib) [ Time Frame: first 28 days of treatment ]
    To estimate the maximum tolerate doses (MTDs) and/or identify the RP2D and schedule of LEE011 and MEK162 combination. A dose-limiting toxicity (DLT) was defined as an AE or clinically significant abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle of treatment with ribociclib and binimetinib.
  • Objective Response Rate (ORR) (Phase II) [ Time Frame: Approximately 12 months after the FPFV ]
    ORR is the proportion of patients with best overall response of complete response (CR) or partial response (PR) by month 2 assessed according to RECIST 1.1 criteria. ORR is done to describe the anti-tumor activity of LEE011 and MEK162 combination. The primary analysis of the ORR was based on the Investigator's assessment of overall lesion responses per RECIST 1.1.
Original Primary Outcome Measures  ICMJE
 (submitted: January 30, 2013)
  • Incidence of dose limiting toxicities (Phase Ib) [ Time Frame: first 28 days of treatment ]
    To estimate the maximum tolerate doses (MTDs) and/or identify the RP2D and schedule of LEE011 and MEK162 combination.
  • Objective Response Rate (ORR) (Phase II) [ Time Frame: Baseline, every 2-4 months ]
    ORR is the proportion of patients with best overall response of complete response (CR) or partial response (PR) by month 2 assessed according to RECIST 1.1 criteria. ORR is done to describe the anti-tumor activity of LEE011 and MEK162 combination.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 24, 2020)
  • Plasma Concentration-time Profile (AUCtau) of LEE011 (Phase Ib) [ Time Frame: Cycle 1 Day 1 ]
    To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (AUCtau) of MEK162 (Phase Ib) [ Time Frame: Cycle 1 Day 1 ]
    To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (AUCtau,ss) of LEE011 (Phase Ib) [ Time Frame: For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 ]
    To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (AUCtau,ss) of MEK162 (Phase Ib) [ Time Frame: For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 ]
    To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (Cmin,ss) of LEE011 (Phase Ib) [ Time Frame: For the 28-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 14 ]
    To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (Cmin,ss) of MEK162 (Phase Ib) [ Time Frame: For the 28-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 14 ]
    To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (Cmax) of LEE011 (Phase Ib) [ Time Frame: Cycle 1 Day 1 ]
    To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (Cmax) of MEK162 (Phase Ib) [ Time Frame: Cycle 1 Day 1 ]
    To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (Cmax,ss) of LEE011 (Phase Ib) [ Time Frame: For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 ]
    To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (Cmax,ss) of MEK162 (Phase Ib) [ Time Frame: For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 ]
    To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (Tmax) of LEE011 (Phase Ib) [ Time Frame: Cycle 1 Day 1 ]
    To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (Tmax) of MEK162 (Phase Ib) [ Time Frame: Cycle 1 Day 1 ]
    To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (Tmax,ss) of LEE011 (Phase Ib) [ Time Frame: For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 ]
    To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (Tmax,ss) of MEK162 (Phase Ib) [ Time Frame: For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 ]
    To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (Accumulation Ratio, Racc_AUC) of LEE011 (Phase Ib) [ Time Frame: For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 ]
    To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (Accumulation Ratio, Racc_AUC) of MEK162 (Phase Ib) [ Time Frame: For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 ]
    To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (T1/2,ss) of LEE011 (Phase Ib) [ Time Frame: For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 ]
    To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (T1/2,ss) of MEK162 (Phase Ib) [ Time Frame: For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14 ]
    To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (CL/F) of LEE011 (Phase Ib) [ Time Frame: Cycle 1 Day 1 ]
    To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).
  • Plasma Concentration-time Profile (CL/F) of MEK162 (Phase Ib) [ Time Frame: Cycle 1 Day 1 ]
    To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Number of Participants With Adverse Drug Reactions [ Time Frame: Approximately 12 months after FPFV ]
    Safety and tolerability will be characterized through the incidence and severity of adverse drug reactions, serious adverse drug reactions, changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, dose reduction and dose intensity.
  • Duration of Response (DoR) - Phase 2 [ Time Frame: Approximately 12 months after the FPFV ]
    To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer. Please note: As clinicaltrials.gov only allows numerical data entry, the value of 999 indicates "not estimable" for confidence interval.
  • Time to Progression (TTP) - Phase 2 [ Time Frame: Approximately 12 months after the FPFV ]
    To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.
  • Progression Free Survival (PFS) - Phase 1b and Phase 2 [ Time Frame: Approximately 12 months after the FPFV ]
    To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer. In the Phase 1b part, patients were combined for purposes of PFS analyses based on schedule received, since too few patients received any individual dose level to allow for valid PFS estimates within the respective dose levels. This is how the data were analyses and presented for the clinical study report.
  • Overall Survival (OS) - Phase ll [ Time Frame: Approximately 12 months after the FPFV ]
    To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.
  • Best Overall Response (BOR) - Phase II [ Time Frame: Approximately 12 months after the FPFV ]
    To assess clinical safety according to RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.
Original Secondary Outcome Measures  ICMJE
 (submitted: January 30, 2013)
  • Plasma concentration-time profile (AUCtau) of LEE011 and MEK162 (phase Ib) [ Time Frame: up to 24 weeks ]
    To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma concentration-time profile (AUCtau,ss) of LEE011 and MEK162 (phase Ib) [ Time Frame: up to 24 weeks ]
    To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma concentration-time profile (Cmin,ss) of LEE011 and MEK162 (phase Ib) [ Time Frame: up to 24 weeks ]
    To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma concentration-time profiles of LEE011 and MEK162 (phase Ib) [ Time Frame: up to 24 weeks ]
    Evaluation of PK parameters, including but not limited to AUCtau, AUCtau,ss, Cmin,ss, Cmax, Cmax,ss ,Tmax, Tmax,ss, accumulation ratio (Racc), and T1/2,acc, CL/F in cycle 1-6. (Phase Ib).
  • Plasma concentration-time profile (Cmax) of LEE011 and MEK162 (phase Ib) [ Time Frame: up to 24 weeks ]
    To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma concentration-time profile (Cmax,ss) of LEE011 and MEK162 (phase Ib) [ Time Frame: up to 24 weeks ]
    To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma concentration-time profile (Tmax) of LEE011 and MEK162 (phase Ib) [ Time Frame: up to 24 weeks ]
    To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma concentration-time profile (Tmax,ss) of LEE011 and MEK162 (phase Ib) [ Time Frame: up to 24 weeks ]
    To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma concentration-time profile (accumulation ration, Racc) of LEE011 and MEK162 (phase Ib) [ Time Frame: up to 24 weeks ]
    To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma concentration-time profile (T1/2, acc) of LEE011 and MEK162 (phase Ib) [ Time Frame: up to 24 weeks ]
    To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Plasma concentration-time profile (CL/F) of LEE011 and MEK162 (phase Ib) [ Time Frame: up to 24 weeks ]
    To Characterize the PK profiles of LEE011 and MEK162 as well as any other significant metabolites identified (Phase Ib).
  • Incidence of adverse drug reactions [ Time Frame: Approximatley 12 months after FPFV ]
    Safety and tolerability will be characterized through the incidence and severity of adverse drug reactions, serious adverse drug reactions, changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, dose reduction and dose intensity.
  • Duration of Response (DoR) - Phase ll [ Time Frame: Approximatley 12 months after the FPFV ]
    To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.
  • Time to Progression (TTP) - Phase ll [ Time Frame: Approximately 12 months after the FPFV ]
    To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.
  • Progression Free Survival (PFS) - Phase ll [ Time Frame: Approximatley 12 months after the FPFV ]
    To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.
  • Overall Survival (OS) - Phase ll [ Time Frame: Approximately 12 months after the FPFV ]
    To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.
  • Best Overall Response (BOR) - Phase ll [ Time Frame: Approximately 12 months after the FPFV ]
    To assess clinical safety according to RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Official Title  ICMJE A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma
Brief Summary In the phase Ib, the primary purpose is to establish the maximum tolerated dose (MTD)(s)/recommended phase ll dose (RP2D) and schedule of LEE011 and MEK162 orally administered combination. Once the MTD(s)/RP2D have been determined for each tested schedule, additional patients will be enrolled in the phase II portion of the study at the RP2D on the chosen schedule in order to assess the anti-tumor activity of the combination in addition to continued evaluation of safety.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Locally Advanced or Metastatic NRAS Mutant Melanoma
Intervention  ICMJE
  • Drug: LEE011
    LEE011 will be administered orally once daily
  • Drug: MEK162
    MEK162 will be administered orally twice daily
Study Arms  ICMJE
  • Experimental: Phase Ib

    The phase Ib is the dose escalation part where successive cohorts of 3-6 newly enrolled patients receiving various dose pairs considering the recommendation from an adaptive BLRM incorporating the EWOC principle until MTD(s)/RP2D is defined. If multiple alternate dosing schedules are explored in parallel, the allocation of patients will proceed in an alternating fashion. Approximately 40 patients are expected to be treated during the phase Ib part of the study.

    Dosing Schedule 1: MEK162 administered orally twice daily on a continuous dosing schedule. LEE011 administered orally once daily for 21 days followed by a 1 week break (28-day cycle).

    Dosing Schedule 2: MEK162 administered orally twice daily and LEE011 administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).

    Dosing Schedule 3: MEK162 administered orally twice daily and LEE011 administered once daily for 2 weeks followed by a 1 week break (21-day cycle).

    Interventions:
    • Drug: LEE011
    • Drug: MEK162
  • Experimental: Phase II

    The Phase II part will begin once the MTD(s)/RP2D have been determined in the Phase Ib in order to assess antitumor activity of the LEE011and MEK162 combination. Patients enrolled in the Phase II part of the study are required to have measurable disease. Approximately 40 patients will be treated in this part.

    Phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination.

    Interventions:
    • Drug: LEE011
    • Drug: MEK162
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 22, 2018)
102
Original Estimated Enrollment  ICMJE
 (submitted: January 30, 2013)
58
Actual Study Completion Date  ICMJE February 20, 2018
Actual Primary Completion Date January 15, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.
  • Patients enrolled into phase Ib may be enrolled with evaluable disease only. Patients enrolled into the phase II expansion must have at least one measurable lesion as defined by RECIST 1.1 criteria for solid tumors.
  • Patients must have adequate organ function, as defined by the following parameter

    1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L.
    2. Hemoglobin (Hgb) ≥ 9 g/dL.
    3. Platelets ≥ 75 x 109/L without transfusions within 21 days before 1st treatment.
    4. PT/INR and aPTT ≤ 1.5 ULN.
    5. Serum creatinine ≤1.5 ULN.
    6. Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN).
    7. AST and ALT ≤ 3 x ULN, except in patients with tumor involvement of the liver who must have AST and ALT ≤ 5 x ULN.

Exclusion Criteria:

  • Presence of any brain metastases detected by MRI or CT with i.v. contrast of the brain at screening.
  • Uncontrolled arterial hypertension despite medical treatment
  • Impaired cardiac function or clinically significant cardiac diseases, including any of the following:

    1. Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition scan (MUGA) or echocardiogram (ECHO).
    2. Congenital long QT syndrome or family history of unexpected sudden cardiac death.
    3. QTcF corrected with Frederica's or Bazett's formula QTcB >450 ms for males and >470 ms for females on screening ECG.
    4. Angina pectoris ≤ 3 months prior to starting study drug
    5. Acute myocardial infarction ≤ 3 months prior to starting study drug
    6. Clinically significant resting bradycardia
    7. History or presence of ventricular tachyarrhythmia
    8. Unstable atrial fibrillation (ventricular response >100 bpm)
    9. Complete left bundle branch block
    10. Right bundle branch block and left anterior hemi block (bifascicular block)
    11. Obligate use of a cardiac pacemaker or implantable cardioverter defibrillator
    12. Any other clinically significant heart disease
  • Patients who are currently receiving treatment with agents that are known to cause QTc prolongation in humans.
  • Patients who have neuromuscular disorders that are associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy) or elevated baseline CK levels (≥ Grade 2)
  • Patients who are currently receiving treatment with agents that are metabolized predominantly through CYP3A4 and that have a narrow therapeutic window.
  • Patients with concurrent severe and/or uncontrolled concurrent medical conditions that could compromise participation in the study (i.e. uncontrolled diabetes mellitus, clinically significant pulmonary disease, clinically significant neurological disorder, active or uncontrolled infection).
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes).

Other protocol related inclusion/exclusion criteria may apply.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Germany,   Italy,   Netherlands,   United States
Removed Location Countries Norway
 
Administrative Information
NCT Number  ICMJE NCT01781572
Other Study ID Numbers  ICMJE CMEK162X2114
C4211005 ( Other Identifier: Pfizer )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Pfizer
Verification Date November 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP